Non-alcoholic Fatty Liver Clinical Trials

86 recruitingLast updated: May 21, 2026

There are 86 actively recruiting non-alcoholic fatty liver clinical trials across 30 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include New York, New York, United States, San Antonio, Texas, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Non-alcoholic Fatty Liver Trials at a Glance

86 actively recruiting trials for non-alcoholic fatty liver are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Not Applicable with 34 trials, with the heaviest enrollment activity in New York, San Antonio, and Boston. Lead sponsors running non-alcoholic fatty liver studies include GlaxoSmithKline, Cairo University, and The University of Hong Kong.

Browse non-alcoholic fatty liver trials by phase

About Non-alcoholic Fatty Liver Clinical Trials

Looking for clinical trials for Non-alcoholic Fatty Liver? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-alcoholic Fatty Liver trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-alcoholic Fatty Liver clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 86 trials

Recruiting
Not Applicable

Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues

Non-Alcoholic Fatty Liver DiseaseSubclinical hypothyroïdismPrimary Open Angle Glaucoma
Cairo University40 enrolled1 locationNCT07599241
Recruiting
Phase 2

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)84 enrolled1 locationNCT03884075
Recruiting
Phase 2

Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

Non-Alcoholic Fatty Liver Disease
Tanta University46 enrolled1 locationNCT06863376
Recruiting

Liver Steatosis in Pediatric CD Patients

Non-Alcoholic Fatty Liver DiseaseCeliac Disease in Children
University of Palermo91 enrolled2 locationsNCT06206616
Recruiting

Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals

Non-Alcoholic Fatty Liver DiseaseLow Birth Weight
Steno Diabetes Center Copenhagen300 enrolled1 locationNCT05890365
Recruiting

CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome

Hepatocellular CarcinomaNon-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis+2 more
Institut National de la Santé Et de la Recherche Médicale, France710 enrolled1 locationNCT05623150
Recruiting

Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

Liver NeoplasmLiver FibrosisHBV Infection+1 more
Nanfang Hospital, Southern Medical University240 enrolled1 locationNCT07265544
Recruiting
Phase 3

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline1,250 enrolled43 locationsNCT07221188
Recruiting
Phase 3

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline1,200 enrolled49 locationsNCT07221227
Recruiting
Phase 1

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline32 enrolled3 locationsNCT07358546
Recruiting
Phase 1

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Insulin ResistanceNon-Alcoholic Fatty Liver DiseaseOverweight and Obesity+1 more
Columbia University32 enrolled1 locationNCT06354088
Recruiting
Phase 1

Effect of Insulin Lowering on Lipogenesis

ObesityInsulin ResistanceNon-Alcoholic Fatty Liver Disease+2 more
Columbia University25 enrolled1 locationNCT07403604
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline30 enrolled1 locationNCT07335198
Recruiting

Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome

Non-Alcoholic Fatty Liver DiseaseAutoimmune HepatitisPrimary Sclerosing Cholangitis+2 more
Chungnam National University Hospital3,000 enrolled1 locationNCT06519162
Recruiting

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

ObesityNon-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
Brigham and Women's Hospital150 enrolled2 locationsNCT05728697
Recruiting
Not Applicable

Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

Non-Alcoholic Fatty Liver Disease
Weill Medical College of Cornell University40 enrolled1 locationNCT05332613
Recruiting

Identification of Liver Fibrosis Biomarkers

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisNon-alcoholic Fatty Liver
Roche Diagnostics GmbH575 enrolled2 locationsNCT06819917
Recruiting

Comorbidities Resolution After MGB Surgery and Change in Body Composition

HypertensionNon-Alcoholic Fatty Liver DiseaseSleep Apnea+5 more
All India Institute of Medical Sciences, Bhubaneswar35 enrolled1 locationNCT06015620
Recruiting

"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".

Liver CancerNon-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis+4 more
Institut National de la Santé Et de la Recherche Médicale, France800 enrolled1 locationNCT04690972
Recruiting
Phase 1

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Nonalcoholic Steatohepatitis (NASH)Metabolic dysfunction-associated steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease NAFLD+1 more
Corcept Therapeutics8 enrolled1 locationNCT06947304